The global cancer biomarker market is expected to grow at a CAGR of 11.32% between the years 2019-2027. Some of the important drivers for the global cancer biomarker market include encouragement by the FDA for biomarker development, the adoption of western lifestyles in developing countries, heavy investments by government and private funds for cancer-related research, etc.
The global cancer biomarker market is segmented into profiling technology which is divided into omic technology, imaging technologies, immunoassays and cytogenetic-based tests. The market is also segmented into biomarker that includes genetic biomarkers, protein biomarkers and glyco biomarkers. The market by cancer type is bifurcated into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer and others cancer type. The application segment is divided into diagnostics, drug discovery and development, prognostics, risk assessment and others.
The global cancer biomarker market is geographically segmented into North America (U.S. & Canada), Asia-Pacific (India, China, Japan, Australia, South Korea, and Rest of APAC), Europe (United Kingdom, Germany, Italy, France, Spain, rest of Europe) and the Rest of World (Latin America, Middle East and North Africa and Rest of Africa). The North American region is the most dominant region in the global market, with the United States acting as the major contributor. Moreover, the Asia-Pacific region is anticipated to be the fastest growing regional market owing to the increasing prevalence of cancer in the region.
Some of the noted companies in the global market are Abbott Laboratories, Agendia N.V., Agilent Technologies, Inc., Aureon Biosciences, Inc., Astellas Pharma Inc., Beckman Coulter, Becton Dickinson and Company, Bristol-Myers Squibb, Celgene Corporation, Clarient, Inc. (Acquired By Neogenomics Laboratories), Diadexus Inc. (Acquired By Diazyme Laboratories), Illumina, Inc., Roche Diagnostics Ltd, Sanofi and Qiagen N.V.